Introduction: COVID-19 pandemic is a global public health threat facing mankind. There is no specific antiviral treatment for COVID-19, and many vaccine candidates are currently under clinical trials. This study aimed to understand the perception of social media users regarding a hypothetical COVID-19 vaccine in Nigeria.
Methods: we conducted a cross-sectional survey among social media users in Nigeria in August 2020 using an online questionnaire. The questionnaire includes sections on the demographic characteristics of the respondents and their perception regarding a hypothetical COVID-19 vaccine. A total of 517 respondents completed and returned the informed consent along with the questionnaire electronically. Data were coded and abstracted into Microsoft Excel spreadsheet and loaded into the STATA 14 software for final analysis.
Results: the results showed that more than half of the respondents were male 294 (56.9%). Most of the respondents 385 (74.5%) intend to take the COVID-19 vaccine when it becomes available. Among the 132 respondents that would not take the COVID-19 vaccine, the major reason for non-acceptance was unreliability of the clinical trials 49 (37.1%), followed by the belief that their immune system is sufficient to combat the virus 36 (27.3%). We found a significant association between the age of the respondents and the COVID-19 vaccine acceptance (P-value=0.00) as well as geographical location and COVID-19 vaccine acceptance (P-value=0.02).
Conclusion: it was observed that most of the respondents were willing to take the COVID-19 vaccine. Our findings also reiterate the need to reassure the public the benefits an effective and safe COVID-19 vaccine can reap for public health. There is a need for national health authorities in Nigeria to ensure public trust is earned and all communities, including the marginalized populations, are properly engaged to ensure an optimal COVID-19 vaccine acceptance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140724 | PMC |
| http://dx.doi.org/10.11604/pamj.2021.38.230.27325 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SARS-CoV-2 surveillance in a hospital and control of an outbreak on a geriatric ward using whole genome sequencing.
Infect Prev Pract
September 2024
SARS-CoV-2 Sequencing Consortium, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Background: During the SARS-CoV-2 pandemic, dominant viral variants were repeatedly replaced by new variants with altered properties, frequently changing the dynamics of the infection event, as well as the effectiveness of vaccines and therapeutics. SARS-CoV-2 variant monitoring by whole genome sequencing was established at the University Medical Center Mainz, Germany to support patient management during the pandemic.
Methods: SARS-CoV-2 RNA samples from the University Medical Center were analysed weekly with whole genome sequencing.
Evaluation of vaccine perceptions in Israel's Elderly: A Comparative study of COVID-19 and influenza vaccination attitudes.
Vaccine X
October 2024
Clinical Microbiology Laboratory, Tzafon Medical Center, Poriya, Israel, affiliated with Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Purpose: This study aimed to evaluate the attitudes of Israeli elderly population towards COVID-19 and influenza vaccines, and to assess factors contributing to these attitudes.
Methods: Four-hundred and one participants exhibiting symptoms consistent with COVID-19 or influenza were enrolled and filled out a questionnaire. A second questionnaire was filled out for hospitalized patients at discharge.
Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial.
BMJ Oncol
December 2023
Université Franche-Comté, INSERM, EFS BFC, UMR1098 RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Objective: Vaccinated patients with cancer in follow-up studies showed a high seropositivity rate but impaired antibody titres and T cell responses following mRNA vaccine against COVID-19. Besides clinical characteristics and the type of anticancer treatment before vaccination, the identification of patients susceptible to non-response following vaccination using immunological markers is worth to be investigated.
Methods And Analysis: All patients (n=138, solid cancers) were included in the CACOV-VAC Study comprising three cohorts ((neo)-adjuvant, metastatic and surveillance).
Post-pandemic insights on COVID-19 and premature ovarian insufficiency.
Open Life Sci
January 2025
Department of Medicine, Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, No. 411 Guogeli Street, Nangang District, Harbin, Heilongjiang, 150006, P.R. China.
The COVID-19 pandemic has raised concerns regarding its potential impact on premature ovarian insufficiency (POI). This overview examines the possible interactions between COVID-19 and POI, while also suggesting preventive measures. The viral infection's inflammatory response and immune dysregulation may adversely affect ovarian tissues, leading to inflammation and damage.
View Article and Find Full Text PDFCOVID-19 vaccine hesitancy among health providers at Kenyatta National Teaching and Referral Hospital Nairobi-Kenya.
Pan Afr Med J
October 2024
School of Public Health Department, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!